Rasayana Therapeutics

Rasayana Therapeutics is a private, pre-revenue biotech founded in 2018 and based in San Diego, CA. The company is advancing a first-in-class, oral biologic platform focused on the gut mucosal interface, with a lead candidate, RSY-248, currently in Phase 2 development for gut inflammation. Rasayana's core thesis is that unresolved gut inflammation is a common driver of chronic conditions like IBD, metabolic disease, and autoimmunity, and that restoring evolutionary conserved biology like IAP can enable more durable disease control. The company is built for speed and impact, aiming to transform chronic disease treatment by targeting the origin of inflammation rather than its downstream symptoms.

Platform centered on oral recombinant Intestinal Alkaline Phosphatase (IAP) designed to restore gut mucosal homeostasis through multimodal mechanisms: detoxifying PAMPs/DAMPs, modulating TLR/purinergic signaling, and restoring epithelial tight junctions to address upstream drivers of systemic inflammation.

Rasayana competes in the broad inflammatory disease market dominated by large pharma's biologic drugs (anti-TNF, IL-12/23, JAK inhibitors). Its direct differentiation is its upstream, oral, multi-target approach. It also competes indirectly with other gut-focused therapies (microbiome modulators, barrier enhancers) but its specific IAP mechanism appears first-in-class.